Table 2.
EBV infected (n = 36) | EBV un-infected (n = 61) | P | |
---|---|---|---|
Sex(male) | 18 (50%) | 34 (55.7%) | 0.584 |
Age (years) | 59.69 ± 12.540 | 53.69 ± 11.725 | 0.020 |
≥ 60 yr | 22 (61.1%) | 20 (32.8%) | 0.007 |
Complications of liver cirrhosis | |||
Ascites | 26 (72.2%) | 40 (65.6%) | 0.498 |
Hepatic encephalopathy | 8 (22.2%) | 13 (21.3%) | 0.916 |
Hepatocellular carcinoma | 2 (5.6%) | 5 (8.2%) | > 0.99 |
Bacterial infection | 15 (41.7%) | 15 (24.6%) | 0.079 |
Gastrointestinal bleeding | 3 (8.3%) | 5 (8.2%) | > 0.99 |
Hepatorenal syndrome | 2 (5.6%) | 5 (8.2%) | > 0.99 |
Transplant-free mortality | |||
28-days mortality | 9 (25.0%) | 11 (18.0%) | 0.413 |
90-days mortality | 10 (27.8%) | 14 (23.0%) | 0.595 |
180-days mortality | 13 (36.1%) | 16 (26.2%) | 0.304 |
Liver function | |||
ALT (U/L) | 103.00 ± 146.315 | 161.25 ± 279.798 | 0.182 |
AST (U/L) | 110.75 ± 104.110 | 138.39 ± 174.436 | 0.331 |
Albumin (g/L) | 30.92 ± 5.861 | 33.65 ± 5.199 | 0.019 |
A/G | 1.05 ± 0.366 | 1.266 ± 0.432 | 0.013 |
TB (uoml/L) | 173.94 ± 160.474 | 163.85 ± 172.967 | 0.776 |
DB (umol/L) | 117.03 ± 111.236 | 110.97 ± 122.289 | 0.808 |
CHE(U/L) | 2914.58 ± 1654.627 | 3638.16 ± 1859.968 | 0.057 |
ALP(U/L) | 149.61 ± 141.881 | 135.52 ± 66.467 | 0.509 |
GGT (U/L) | 111.19 ± 154.451 | 126.75 ± 164.061 | 0.646 |
Liver size | 8.58 ± 0.826 | 8.49 ± 0.774 | 0.612 |
Spleen size | 4.78 ± 1.369 | 4.47 ± 1.454 | 0.299 |
Child-pugh Score | 9.83 ± 2.864 | 8.64 ± 2.470 | 0.033 |
Meld Score | 18.33 ± 22.693 | 12.50 ± 9.995 | 0.084 |
ACLF | 8 (22.2%) | 5 (8.2%) | 0.050 |
ACLF grade 1 | 2 (5.6%) | 1 (1.6%) | 0.553 |
ACLF grade 2 | 6 (16.7) | 3 (4.9%) | 0.073 |
ACLF grade 3 | 0 (0.0%) | 1 (1.6%) | > 0.99 |
ALT alanine aminotransferase, AST aspartate aminotransferase, A/G Albumin/Globulin, TB total bilirubin, DB direct bilirubin, GGT γ-glutamyl transpeptadase, CHE cholinesterase, ALP alkaline phosphatase, Meld score model for end-stage liver disease score, ACLF acute-on-chronic liver failure